lunes, 22 de octubre de 2018

AzurRx Biopharma to Launch MS1819-SD Trial for CF Patients with EPI

AzurRx Biopharma to Launch MS1819-SD Trial for CF Patients with EPI

Cystic Fibrosis News Today



FDA Approves AzurRx Biopharma Request to Test MS1819-SD in CF Patients with EPI

No hay comentarios:

Publicar un comentario